Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 6/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5419816 | 0.88 | FDPS (0.42) | FDPSALOX15SMPD1 | |
| SCHEMBL450544 | 0.85 | MEN1 (0.32) | FDPSALOX15LMNAADRB3PDE4D | |
| SCHEMBL6811305 | 0.78 | FDPS (0.39) | FDPSALOX15PDE3AALDH1A1HSD17B10 | |
| SCHEMBL8474061 | 0.78 | FDPS (0.39) | FDPSALOX15LMNAALDH1A1HSD17B10 | |
| Phosphine SCHEMBL27681919 | 0.77 | FDPS (0.38) | FDPSALOX15PDE3AALDH1A1HSD17B10 | |
| SCHEMBL6579146 | 0.76 | GABRR1 (0.33) | — | |
| SCHEMBL2199441 | 0.76 | ODC1 (0.36) | FDPSLMNAPDE3A | |
| Hydrochloric Acid SCHEMBL3508614 | 0.76 | FDPS (0.38) | FDPSALOX15LMNAALDH1A1HSD17B10 | |
| SCHEMBL225787 | 0.75 | GGPS1 (0.45) | FDPSSMPD1 | |
| SCHEMBL6058687 | 0.75 | GGPS1 (0.45) | FDPSSMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140004461-A1 | TONER FOR ELECTROSTATIC LATENT IMAGE DEVELOPMENT AND METHOD FOR PRODUCING TONER FOR ELECTROSTATIC LATENT IMAGE DEVELOPMENT | KYOCERA DOCUMENT SOLUTIONS INC. (JP) | 2014-01-02 | — | — | US | disclosed |
| US-20040208834-A1 | Oral-use polymer and oral-use composition | KAO CORPORATION (JP) | 2004-10-21 | — | — | US | disclosed |
| EP-1413589-A1 | POLYMERS FOR ORAL USE AND COMPOSITIONS FOR ORAL USE | Kao Corporation (JP) | 2004-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040208834-A1 | Oral-use polymer and oral-use composition | PHOSPHO1, PPA1, PHPT1 | FDPS 556/4885ALOX15 752/4885LMNA 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.